"Monoclonal Antibodies for Treatment of Multiple Myeloma. Emphasis on the CD38 Antibody Daratumumab "
Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
Daratumumab is a new treatment for patients with myeloma. While many patients benefit from
this treatment some do not and the mechanism(s) of failure are poorly understood. This study
aims to clarify aspects of resistance to treatment with daratumumab in order to improve
patient outcomes in the future.